Second Time A Charm? Enzon Sells Biotech Business To Italian Pharma
One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.
One year after a failed effort to sell off its biotech business, Enzon will bring in $300 million by selling its four specialty drugs to Sigma-Tau.